Elanco Animal Health (ELAN) News Today

Elanco Animal Health (NYSE: ELAN) shares have risen on the back of a strong second-quarter earnings beat, upward guidance revisions and positive analyst actions. Below are the key recent developments influencing investor sentiment:

• Positive Sentiment: Elanco stock jumped nearly 20% to a record high after reporting Q2 results that significantly beat expectations. Elanco Jumps to Record High
• Positive Sentiment: UBS raised its price target on ELAN from $18 to $19 and reiterated a “buy” rating, implying over 14% upside. Benzinga
• Positive Sentiment: The company lifted its FY 2025 guidance, now expecting EPS of $0.85–$0.91 (vs. $0.84 consensus) and revenue around $4.6 billion (vs. $4.5 billion consensus). MarketBeat FY Guidance
• Positive Sentiment: Innovation revenue outlook was raised to $720 million–$800 million for 2025, signaling margin expansion from new product launches. MSN Innovation Outlook
• Positive Sentiment: Shares hit a new 12-month high following the earnings beat, reflecting strong investor confidence. Elanco Hits New 12-Month High
• Positive Sentiment: Elanco set Q3 guidance for EPS of $0.12–$0.16 (consensus $0.134) and revenue in line with estimates, indicating steady near-term visibility. MarketBeat Q3 Guidance
• Positive Sentiment: Multiple outlets highlighted a 5% year-over-year jump in Q2 revenue, underlining growth in Elanco’s core animal-health business. The Globe and Mail
• Positive Sentiment: Seeking Alpha analysts initiated coverage with a “Buy” rating and $20 fair value, citing rising innovation revenues and operational improvements. Seeking Alpha Buy Initiation
• Neutral Sentiment: Analyst reports and stock forecasts were updated in light of the Q2 results, refining longer-term estimates. Yahoo Research
• Neutral Sentiment: Full Q2 earnings call transcript and presentation slides are now available for investors seeking detailed commentary from management. Earnings Call Transcript